| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
35,915,000 |
| Market
Cap: |
4.57(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$36.74 - $124.44 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile TransMedics Group is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across various disease states. Co. has developed the Organ Care System (OCS), a portable organ perfusion and monitoring system that using Co.'s technology to replicate near-physiologic conditions for donor organs outside of the human body. The OCS was designed to perfuse donor organs with warm, oxygenated and nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. Co.'s OCS products are one for each of lung, heart and liver transplantations.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,500 |
2,500 |
| Total Buy Value |
$0 |
$0 |
$155,000 |
$155,000 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
271,054 |
342,899 |
405,806 |
1,060,395 |
| Total Sell Value |
$27,491,657 |
$33,196,965 |
$37,923,912 |
$74,654,923 |
| Total People Sold |
4 |
6 |
6 |
10 |
| Total Sell Transactions |
21 |
30 |
40 |
119 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Carey John F |
VP of Operations |
• – – |
2022-07-11 |
4 |
OE |
$16.14 |
$24,210 |
D/D |
1,500 |
1,879 |
|
- |
|
| Khayal Tamer I |
Chief Commercial Officer |
• – – |
2022-07-05 |
4 |
AS |
$35.06 |
$473,450 |
D/D |
(13,504) |
46,076 |
|
60% |
|
| Khayal Tamer I |
Chief Commercial Officer |
• – – |
2022-07-05 |
4 |
OE |
$0.28 |
$3,781 |
D/D |
13,504 |
59,580 |
|
- |
|
| Tobin James R |
Director |
– • – |
2022-07-05 |
4 |
AS |
$35.00 |
$1,698,025 |
I/I |
(48,515) |
302,106 |
|
60% |
|
| Gordon Stephen |
Chief Financial Officer |
• – – |
2022-07-05 |
4 |
AS |
$35.00 |
$350,000 |
D/D |
(10,000) |
5,714 |
|
60% |
|
| Gordon Stephen |
Chief Financial Officer |
• – – |
2022-07-05 |
4 |
OE |
$2.21 |
$22,100 |
D/D |
10,000 |
15,714 |
|
- |
|
| Carey John F |
VP of Operations |
• – – |
2022-06-28 |
4 |
AS |
$32.87 |
$89,538 |
D/D |
(2,724) |
379 |
|
85% |
|
| Carey John F |
VP of Operations |
• – – |
2022-06-28 |
4 |
OE |
$0.28 |
$763 |
D/D |
2,724 |
3,103 |
|
- |
|
| Carey John F |
VP of Operations |
• – – |
2022-06-27 |
4 |
AS |
$32.59 |
$108,199 |
D/D |
(3,320) |
379 |
|
74% |
|
| Carey John F |
VP of Operations |
• – – |
2022-06-27 |
4 |
OE |
$0.28 |
$930 |
D/D |
3,320 |
3,699 |
|
- |
|
| Carey John F |
VP of Operations |
• – – |
2022-06-24 |
4 |
AS |
$32.57 |
$96,277 |
D/D |
(2,956) |
379 |
|
44% |
|
| Carey John F |
VP of Operations |
• – – |
2022-06-24 |
4 |
OE |
$0.28 |
$828 |
D/D |
2,956 |
3,335 |
|
- |
|
| Carey John F |
VP of Operations |
• – – |
2022-06-01 |
4 |
AS |
$27.89 |
$42,279 |
D/D |
(1,500) |
379 |
|
49% |
|
| Carey John F |
VP of Operations |
• – – |
2022-06-01 |
4 |
OE |
$0.28 |
$420 |
D/D |
1,500 |
1,879 |
|
- |
|
| Carey John F |
VP of Operations |
• – – |
2022-04-01 |
4 |
AS |
$26.85 |
$40,275 |
D/D |
(1,500) |
379 |
|
71% |
|
| Carey John F |
VP of Operations |
• – – |
2022-04-01 |
4 |
OE |
$0.28 |
$420 |
D/D |
1,500 |
1,879 |
|
- |
|
| Carey John F |
VP of Operations |
• – – |
2022-03-28 |
4 |
AS |
$25.01 |
$112,545 |
D/D |
(4,500) |
379 |
|
95% |
|
| Carey John F |
VP of Operations |
• – – |
2022-03-28 |
4 |
OE |
$0.28 |
$48,827 |
D/D |
4,500 |
4,879 |
|
- |
|
| Hassanein Waleed H |
President & CEO |
• • – |
2022-01-06 |
4 |
OE |
$0.28 |
$34,264 |
D/D |
122,371 |
526,214 |
|
- |
|
| Provost Miriam |
VP of US Regulatory & FDA Rel. |
• – – |
2021-12-23 |
4 |
OE |
$3.22 |
$2,846 |
D/D |
884 |
9,438 |
|
- |
|
| Tobin James R |
Director |
– • – |
2021-12-15 |
4 |
GD |
$0.00 |
$0 |
I/I |
25,500 |
399,137 |
|
- |
|
| Kania Edwin M Jr |
Director |
– • – |
2021-11-29 |
4 |
B |
$22.14 |
$2,256,215 |
D/D |
100,000 |
302,893 |
2.39 |
17% |
|
| Carey John F |
VP of Operations |
• – – |
2021-11-01 |
4 |
AS |
$28.16 |
$47,309 |
D/D |
(1,680) |
0 |
|
-37% |
|
| Carey John F |
VP of Operations |
• – – |
2021-11-01 |
4 |
OE |
$2.21 |
$3,713 |
D/D |
1,680 |
1,680 |
|
- |
|
| Carey John F |
VP of Operations |
• – – |
2021-10-01 |
4 |
AS |
$31.76 |
$54,317 |
D/D |
(1,680) |
0 |
|
-54% |
|
350 Records found
|
|
Page 9 of 14 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.06 (0.05%) 
